
Neuro Oncology
Contact Info
-
+123+456-7890
-
sarahlee@prohealth.com
Appointment Schedules
- Monday 09.00-12.00
- Wednesday 15.00-18.00
- Friday 09.00-12.00
Dr. Patrick Wen
MD
Professor of Neurology, Harvard Medical School Director, Centre for Neuro-Oncology, Dana-Farber Cancer Institute Boston, MA, USA
Degrees
-
University of California, San Francisco.
Medical degree
-
University of California, Los Angeles (UCLA) Medical Center.
Completed residency training in psychiatry
-
University of California, Berkeley.
Master of Public Health degree
Experiences
-
Worked in community mental health clinics, private practice, and academic medical centers.
-
Expertise in the treatment of mood disorders, anxiety disorders, and psychotic disorders.
-
Special interest in womens mental health and perinatal psychiatry.
-
Experience managing complex cases that involve both mental health and medical issues.
Awards/Achievements
-
Fellow of the American Psychiatric Association (FAPA).
-
Recognized for research contributions with grants from the National Institute of Mental Health (NIMH) and the American Foundation for Suicide Prevention.
Dr. Patrick Y Wen, MD is Professor of Neurology at Harvard Medical School, and Director of the Center for Neuro-Oncology at Dana-Farber Cancer Institute in Boston, MA. He graduated from the Medical College of St. Bartholomew's Hospital, University of London, and completed his Internal Medicine training at University of London postgraduate hospitals, and Neurology residency through the Harvard-Longwood Neurology Training Program. His research focuses on novel treatments of brain tumors, especially targeted molecular agents. Dr Wen has authored or co-authored hundreds of peer-reviewed articles that have been published in journals such as Neurology, Neuro-Oncology, Current Opinion in Neurology, and Journal of Clinical Oncology. He is a former President of the Society For Neuro-Oncology, Editor-In-Chief of Neuro-Oncology and Principal Investigator of the Adult Brain Tumor Consortium. He is currently co-chair of the National Cancer Institute Brain Malignancy Steering Committee. His research is focused on novel therapies for brain tumors, especially gliomas, as well as improving clinical trial design and response assessment.
